Thrombocytopenia Clinical Trials 2023

What are the top hospitals conducting thrombocytopenia research?

In the realm of clinical trials focused on thrombocytopenia, several leading hospitals are making significant strides in improving treatments and outcomes for patients. One notable institution is the National Institutes of Health Clinical Center located in Bethesda. With four ongoing thrombocytopenia trials and a total of six conducted over time, this facility has been at the forefront of research since their first recorded trial in 2016. In New york City, Memorial Sloan Kettering Cancer Center (All Protocol Activities) is also dedicated to advancing knowledge in this field. Currently undertaking three active thrombocytopenia trials and having completed three historically, they initiated their inaugural trial as recently as 2020.

Additionally contributing to the progress against thrombocytopenia is Texas Children's Hospital situated in Houston. The hospital currently has three ongoing clinical trials for this condition while having already accomplished six previous investigations since embarking on its journey with a pioneering trial back in 2005. Meanwhile, American Oncology Partners of Maryland, PA based out of Bethesda focuses on addressing thrombocytopenia with an equal emphasis by conducting three active clinical tests and holding records for successfully finishing just as many prior endeavors; all starting from1993.

Lastly Massachusetts General Hospital Cancer Center based within Boston also actively participates with ongoing investigations closeby.They conduct similar number laboratory examinations being involved into researching regarding symptoms related to low platelet count showing alarming signs under category 'thrombo-cyto-penia' which was only brought forward during last two years bearing fruitful results.This included initiationof pathbreaking experimentsto take leaps fowards through exploring potential cures that can help patients suffering globally

These esteemed hospitals collectively showcase dedication towards understanding thrombocytopenia better so that innovative interventions can be developed to alleviate its severity and impact on individuals affected by this condition worldwide

Which are the best cities for thrombocytopenia clinical trials?

When it comes to thrombocytopenia clinical trials, several cities stand out for their ongoing research efforts. New york, New York and Bethesda, Maryland both have 12 active trials exploring treatments like Oral Azacitidine, Eltrombopag, Romiplostim, Avatrombopag, and PF-06835375. Boston, Massachusetts follows closely behind with 11 ongoing studies investigating Romiplostim, Experimental: Avatrombopag and PRN1008 among others. Additionally, Columbus Ohio and Philadelphia Pennsylvania each have 10 active trials focusing on treatments that include Experimental: Avatrombopag and Oral Azacitidine. These cities offer individuals with thrombocytopenia access to cutting-edge clinical trials aimed at finding new approaches to manage this condition effectively.

Which are the top treatments for thrombocytopenia being explored in clinical trials?

Thrombocytopenia, a condition characterized by low platelet count, is the focus of ongoing clinical trials exploring potential treatments. Leading the pack is romiplostim, which is currently being tested in four active trials for thrombocytopenia. Since its introduction in 2004, it has been involved in a total of 28 trials dedicated to addressing this condition. Another contender worth noting is avatrombopag, with two active and 19 all-time thrombocytopenia trials since its debut in 2009. The novel drug fostamatinib has also entered the scene with two ongoing studies focused on treating thrombocytopenia; it was first listed just recently in 2023. Additionally, whole blood transfusion shows promise as an emerging treatment option supported by one active trial specifically targeting thrombocytopenia since its listing also began in 2023. These innovative approaches offer hope for improving outcomes for individuals living with thrombocytopenia as research continues to progress.

What are the most recent clinical trials for thrombocytopenia?

Recent clinical trials have shown promising results in the treatment of thrombocytopenia, a condition characterized by low platelet counts. Avatromopag, povetacicept 240mg, Danazol Pill, Active, and fostamatinib have all been investigated for their efficacy in addressing this disorder. These trials encompassed various phases and were made accessible at different times throughout the year. The findings from these studies provide hope for improved management strategies to combat thrombocytopenia and ultimately enhance patient outcomes.

What thrombocytopenia clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of thrombocytopenia research. In March 2022, Veralox Therapeutics wrapped up a trial investigating the potential of VLX-1005 to address this condition. Bioverativ, a Sanofi company, completed their BIVV020 trial in February 2021, adding to our understanding of effective treatments for thrombocytopenia. Additionally, UCB Biopharma SRL concluded their Rozanolixizumab study in December 2020. These advancements mark important steps forward and offer hope for patients dealing with thrombocytopenia.